New treatments targeting advanced prostate cancer cells
Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa Cells
This study is looking for new ways to treat advanced prostate cancer by focusing on both the main cancer cells and the tougher stem-like cells that don’t respond well to current treatments, with the goal of helping patients who have metastatic castration-resistant prostate cancer feel better and live longer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11167126 on NIH RePORTER |
What this research studies
This research focuses on developing innovative strategies to address the challenges posed by advanced prostate cancer, particularly the diverse and adaptable nature of cancer cells. It aims to target both the bulk of prostate cancer cells and a specific population of stem-like cells that are resistant to current therapies. By understanding the relationship between different types of prostate cancer cells, the research seeks to improve treatment outcomes for patients with metastatic castration-resistant prostate cancer. The approach involves studying the characteristics of these cells and identifying new therapeutic targets to enhance treatment efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are American men diagnosed with advanced or metastatic prostate cancer, particularly those who have developed resistance to standard androgen deprivation therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for advanced prostate cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting cancer stem cells and addressing treatment resistance in various cancers, suggesting that this approach could be beneficial for prostate cancer as well.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Tang, Dean G. — Roswell Park Cancer Institute Corp
- Study coordinator: Tang, Dean G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.